Importantly, two independent studies with MDM2 inhibitors, which both reactivated p53 and downregulated ZEB1, also documented decreased stemness features and glioblastoma aggressiveness (Giacomelli et al., 2017; Her et al., 2018). The gene discussed is ZEB1; the disease is glioblastoma.